CASI Pharmaceuticals sells Alesta stake to BioMarin for US$5.9 million
CASI•CASI completes sale of Alesta equity interests
CASI Pharmaceuticals sold its equity interests in Alesta to BioMarin as part of BioMarin’s acquisition of Alesta.
The deal closed on Aug. 31, 2026, generating about US$5.9 million in net cash proceeds at closing.
Additional contingent milestone payments may be payable, subject to specified development and regulatory triggers.
BioMarin structured the acquisition to keep ALE1 within Alesta, following a pre-close spin-out of non-ALE1 assets.
CASI’s licensed rights to CID-103 were not changed by the transaction.
